MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584163 | Name: Befunolol HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Befunolol is a beta blocker with intrinsic sympathomimetic activity used in the management of open-angle glaucoma. It also acts as a β adrenoreceptor partial agonist. Befunolol was introduced in Japan in 1983 by Kakenyaku Kako Co. under the trade name Bentos.

Chemical Structure

Befunolol HCl
Befunolol HCl
CAS#39543-79-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 584163

Name: Befunolol HCl

CAS#: 39543-79-8 (HCl)

Chemical Formula: C16H22ClNO4

Exact Mass:

Molecular Weight: 327.80

Elemental Analysis: C, 58.63; H, 6.76; Cl, 10.81; N, 4.27; O, 19.52

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
39543-79-8 (HCl) 39552-01-7 (free base)
Synonym
Befunolol HCl; Befunolol hydrochloride; Bentox; BFE 60; BFE-60; BFE60; Glauconex.
IUPAC/Chemical Name
Ethanone, 1-(7-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)-, hydrochloride
InChi Key
TVVTWOGRPVJKDJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H21NO4.ClH/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14;/h4-7,10,13,17,19H,8-9H2,1-3H3;1H
SMILES Code
CC(C1=CC2=CC=CC(OCC(O)CNC(C)C)=C2O1)=O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 327.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nino M, Balato A, Ayala F, Balato N. Allergic contact dermatitis due to levobunolol with cross-sensitivity to befunolol. Contact Dermatitis. 2007 Jan;56(1):53-4. PubMed PMID: 17177718. 2: Shehata MA, El-Sayed GM, Abdel-Fattah LE. Utilization of 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) for kinetic spectrophotometric assay of befunolol hydrochloride in its pharmaceutical formulation. J AOAC Int. 2006 May-Jun;89(3):646-50. PubMed PMID: 16792064. 3: Reichl S, Müller-Goymann CC. The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride. Int J Pharm. 2003 Jan 2;250(1):191-201. PubMed PMID: 12480285. 4: Nino M, Suppa F, Ayala F, Balato N. Allergic contact dermatitis due to the beta-blocker befunolol in eyedrops, with cross-sensitivity to carteolol. Contact Dermatitis. 2001 Jun;44(6):369. PubMed PMID: 11380552. 5: Zucchelli V, Silvani S, Vezzani C, Lorenzi S, Tosti A. Contact dermatitis from levobunolol and befunolol. Contact Dermatitis. 1995 Jul;33(1):66-7. PubMed PMID: 7493479. 6: Koike K, Horinouchi T, Takayanagi I. Comparison of interactions of R(+)- and S(-)-isomers of beta-adrenergic partial agonists, befunolol and carteolol, with high affinity site of beta-adrenoceptors in the microsomal fractions from guinea-pig ciliary body, right atria and trachea. Gen Pharmacol. 1994 Nov;25(7):1477-81. PubMed PMID: 7896063. 7: Maruyama Y, Tanonaka K, Niwa T, Takeo S. Beneficial effects of befunolol on post-hypoxic recovery of cardiac contractility and myocardial metabolism. Arzneimittelforschung. 1992 Dec;42(12):1423-9. PubMed PMID: 1363193. 8: Fusco R, Greco GM, Del Prete A, Caccavale A, Nieto G, Sabbatino S, Santilli F. Long-term effects of befunolol on the corneal endothelium and the consensual ophthalmotonic reaction. Clin Ther. 1992 Nov-Dec;14(6):785-90. PubMed PMID: 1363082. 9: Mancuso G. Allergic contact dermatitis due to befunolol in eyedrops. Contact Dermatitis. 1992 Sep;27(3):198. PubMed PMID: 1360394. 10: Maruyama Y, Awaji T, Inoue M, Takeo S. Protective effects of befunolol on hypoxic respiration-induced alterations in myocardial energy metabolism of rats. Arzneimittelforschung. 1991 Oct;41(10):1022-6. PubMed PMID: 1799378. 11: Takayanagi I, Hagiwara H, Koike K, Hosokawa T, Kasuya Y. Effects of the R(+)- and S(-)-isomers of beta-adrenoceptor blockers with intrinsic sympathomimetic activity, befunolol and carteolol, on rabbit intraocular pressure. Can J Physiol Pharmacol. 1991 Aug;69(8):1243-5. PubMed PMID: 1685941. 12: Koike K, Hagiwara H, Takayanagi I. Comparison of interactions of R-(+)- and S-(-)-isomers of beta-adrenergic partial agonists, befunolol and carteolol, with high affinity site of beta-adrenoceptors in isolated rabbit ciliary body and guinea-pig taenia caeci. Can J Physiol Pharmacol. 1991 Jul;69(7):951-7. PubMed PMID: 1683268. 13: Maruyama Y, Awaji T, Inoue M, Takeo S. Metabolic profile of beta-adrenoceptor-blocking action of befunolol. Arch Int Pharmacodyn Ther. 1991 May-Jun;311:73-88. PubMed PMID: 1686392. 14: Imamura Y, Nozaki Y, Higuchi T, Otagiri M. Reactivity for prostaglandins and inhibition by nonsteridal anti-inflammatory drugs of rabbit liver befunolol reductase. Res Commun Chem Pathol Pharmacol. 1991 Jan;71(1):49-57. PubMed PMID: 2024065. 15: Höh H. [The local anesthetic effect and subjective tolerance of 0.5% befunolol and 1% pindolol in healthy eyes]. Klin Monbl Augenheilkd. 1990 Apr;196(4):219-24. German. PubMed PMID: 1971855. 16: Nozaki Y, Imamura Y, Otagiri M. Kinetics of befunolol reductase from rabbit liver. Chem Pharm Bull (Tokyo). 1990 Jan;38(1):156-8. PubMed PMID: 2186874. 17: Yang L, Zheng JM. [Use of derivative UV spectroscopy to monitor the percutaneous absorption of befunolol-HCL]. Yao Xue Xue Bao. 1990;25(12):916-9. Chinese. PubMed PMID: 2104471. 18: Dorigo MT, Cerin O, Fracasso G, Altafini R. Cardiovascular effects of befunolol, betaxolol and timolol eye drops. Int J Clin Pharmacol Res. 1990;10(3):163-6. PubMed PMID: 1977708. 19: Takayanagi I, Ogishima M, Koike K. Thermodynamic analysis of beta-adrenergic partial agonists (befunolol and carteolol) interaction with low and high affinity binding sites of beta-adrenoceptors in guinea-pig taenia caecum. Gen Pharmacol. 1990;21(3):303-7. PubMed PMID: 1971246. 20: Imamura Y, Nozaki Y, Otagiri M. Purification and characterization of befunolol reductase from rabbit liver. Chem Pharm Bull (Tokyo). 1989 Dec;37(12):3338-42. PubMed PMID: 2698771.